Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2134)	6/14/2003 8:47:24 PM
From: tuck	Read Replies (2) \| Respond to of 2243

OK, so GERN has proven me wrong. Strong PR can trump FA. I will indeed let Allan say when to sell here. And hey, Allan, congratulations on a good call, after all! About the timing on my own pick, ARDM. I've found an apparent inconsistency in the reporting of its inhaled insulin trial that troubles me. ARDM has spiked hard on a note from a Punk Ziegel analyst, one Matt Kaplan, who suggested that good results will be presented at ADA. The abstracts are now available, and what I see -- compared to what was reported on the same trial nine months ago at EASD -- concerns me. Message 19032549 and subsequent post. If we can find out what is said at the meeting tomorrow before Monday, we'll know whether to hold on or to bail. I gather ARDM went over three bucks AH Friday, so that's two home runs so far, but I'm worried about the rest of the game. Commentary invited, no begged. My Mom is still in this one. TIA & Cheers, Tuck